Managing Residual Disease After Neoadjuvant Treatment: T-DM1 and an MRD-Guided Approach
In this article
Optimizing adjuvant therapy, biological mechanisms of resistance and the role of liquid biopsy in decisions for HR+/HER2+ breast cancer without a pathological complete response (pCR).
Introduction and Clinical Rationale: Advances in HER2-positive breast cancer treatment over the past twenty years have changed the natural history of the disease and dramatically improved prognosis. The current standard approach for patients with locally advanced disease (Stage II-III), neoadjuvant (preoperative) systemic therapy, not only reduces the extent of surgery but also allows the tumor's drug sensitivity to be tested in vivo in the living body.
The absence of viable tumor cells in the surgical specimen after neoadjuvant therapy, or pathological complete response (pCR), is the strongest prognostic marker of long-term survival. However, patients with residual disease, meaning remaining tumor tissue despite intensive systemic therapy, are at high risk of recurrence. This article examines clinical challenges such as treatment fatigue and resistance to treatment escalation, particularly common in the hormone receptor (HR)-positive subgroup, using the KATHERINE trial's long-term findings and minimal residual disease (MRD) technologies.
Clinical Scenario and Risk Stratification
The following case illustrates residual disease often encountered in practice: anatomically small, but biologically significant.
Case Summary
The Clinical Dilemma: The patient believes that treatment worked well because the axillary lymph nodes are clear (ypN0). Exhausted after 6 cycles of intensive chemotherapy, she requests an antibody-only regimen (Trastuzumab+Pertuzumab/HP) instead of the standard recommendation, T-DM1.
At this point, the physician's role is to explain "clonal selection" . A 9 mm tumor at stage ypT1b is not equivalent to an untreated 9 mm tumor. These cells are a population with strong survival capacity that has resisted taxane- and platinum-based chemotherapy and dual HER2 blockade. Continuing the existing treatment (HP) may therefore be insufficient against these resistant clones.
An Evidence-Based Approach: Analysis of the KATHERINE Trial
The Phase III KATHERINE trial compared T-DM1 (ado-trastuzumab emtansine) with trastuzumab in patients with residual invasive disease after neoadjuvant therapy. The study demonstrated one of the most pronounced survival advantages in modern oncology.
Efficacy Findings (Median Follow-Up: 8.4 Years)
T-DM1 Arm
Trastuzumab Arm
Subgroup Analyses (Hazard Ratio < 1.0 Favors T-DM1)
*Although there were few events in the small-tumor-burden subgroup, the trend toward reduced risk continued to favor T-DM1.
T-DM1: Pharmacological Mechanism and Side Effect Management
A patient's concern about receiving chemotherapy can be addressed by explaining how T-DM1, an antibody-drug conjugate, works. T-DM1 has a pharmacokinetic profile different from that of conventional systemic chemotherapy.
- Targeting: The trastuzumab antibody binds with high affinity to the HER2 receptor on the tumor cell surface. At this stage, the cytotoxic agent (DM1) is stable and is not active in the systemic circulation.
- Internalization (Cellular Uptake): The antibody-receptor complex is taken into the tumor cell through endocytosis.
- Intracellular Release: Proteolytic breakdown in lysosomes releases the cytotoxic payload (DM1).
- Microtubule Inhibition: DM1 blocks the cell's division machinery, the microtubules, triggering apoptosis (programmed cell death). This maximizes activity within the tumor while minimizing systemic exposure.
Safety Profile Comparison: T-DM1 vs. the HP Regimen
| Side Effect Parameter | T-DM1 (Recommended) | HP (Trastuzumab+Pertuzumab) |
|---|---|---|
| Predominant Toxicity | Thrombocytopenia (Grade 3-4: 5.7%) Usually asymptomatic, with a low risk of bleeding. |
Diarrhea Grade 3 diarrhea occurred in 9.8% of patients in the APHINITY trial. |
| Alopecia (Hair Loss) | Not observed. | Not observed. |
| Effect on Quality of Life | Laboratory abnormalities predominate; physical symptoms are limited. | Chronic diarrhea can restrict a patient's social life and daily activities. |
Future Perspectives: Minimal Residual Disease (MRD) and Decision-Making
For residual disease cases in clinical gray areas, liquid biopsy (ctDNA) is emerging as a biomarker for personalized treatment decisions. Analysis of circulating tumor DNA (ctDNA) can detect molecular relapse months before radiological recurrence, providing lead time.
Detectable tumor DNA in postoperative plasma indicates systemic micrometastatic disease.
- Very High Risk of Recurrence
- Standard Treatment (T-DM1) Is Essential
- Consider a clinical trial (T-DM1 + Tucatinib, etc.).
No disease has been detected at the molecular level. However, the test's sensitivity limitations and potential false negatives must not be overlooked.
- Lower Risk of Recurrence
- If T-DM1 is not tolerated or is declined, this provides supporting information for switching to HP + endocrine therapy.
DROZDOGAN Academy Commentary
Success in oncology depends on more than prescribing the strongest drug; it requires integrating biological realities with the patient's psychosocial circumstances. Although the ypT1b tumor in this case appears numerically small, biologically it has evolved treatment resistance. We must therefore acknowledge the patient's treatment fatigue while clearly explaining T-DM1's proven effect on survival in the KATHERINE findings.
T-DM1 is a sophisticated targeted biological agent rather than a conventional chemotherapy regimen. Its side effect profile differs from the alopecia (hair loss) and severe fatigue the patient fears. In the future, MRD (ctDNA) results alongside pathology reports will help guide these decisions more precisely. Until then, maintaining evidence-based standards (T-DM1) remains the safest course.
- von Minckwitz G, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer (KATHERINE). N Engl J Med. 2019;380:617-628.
- Loibl S, et al. Adjuvant T-DM1 vs Trastuzumab in Early High-Risk HER2-Positive Breast Cancer (KATHERINE): Overall Survival Analysis. SABCS 2023, GS01-12.
- Piccart M, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer (APHINITY): 8-Year Update. J Clin Oncol. 2022.
- Garcia-Murillas I, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.